For the quarter ended June 2025, Addus HomeCare (ADUS) reported revenue of $349.44 million, up 21.8% over the same period last year. EPS came in at $1.49, compared to $1.35 in the year-ago quarter.
The reported revenue represents a surprise of +0.4% over the Zacks Consensus Estimate of $348.04 million. With the consensus EPS estimate being $1.45, the EPS surprise was +2.76%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Addus HomeCare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Personal care: $269.18 million versus the two-analyst average estimate of $265.88 million. The reported number represents a year-over-year change of +26.5%.
- Revenue- Home Health: $18.05 million versus the two-analyst average estimate of $18.26 million. The reported number represents a year-over-year change of -0.2%.
- Revenue- Hospice: $62.21 million versus $61.32 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +11% change.
View all Key Company Metrics for Addus HomeCare here>>>
Shares of Addus HomeCare have returned -6.2% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Addus HomeCare Corporation (ADUS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
